Methods for therapy of neurodegenerative disease of the brain
US6683058B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 19, 2000 |
| Grant date | Jan 27, 2004 |
| Priority date | — |
| Expiry date | Jul 19, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/021
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified defective, diseased or damaged brain cells. Using a viral vector, the concentration of neurotrophin delivered as part of a neurotrophic composition varies from 1010 to 1015 neurotrophin encoding viral particles/ml of composition fluid. Each delivery site receives from 2.5 &mgr;l to 25 &mgr;l of neurotrophic composition, delivered slowly, as in over a period of time ranging upwards of 10 minutes/delivery site. Each delivery site is at, or within 500 &mgr;m of, a targeted cell, and no more than about 10 mm from another delivery site. Stable in situ neurotrophin expression can be achieved for 12 months, or longer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.